Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757288 · ClinicalTrials.gov registry record · Phase 1
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A Phase 1 study of Stage Iiia/b Nsclc / Inoperable Lung Cancer, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 5
- Study locations
NCT01757288 is a Phase 1 study of Stage Iiia/b Nsclc / Inoperable Lung Cancer that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 98 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT01757288, a Phase 1 study of Stage Iiia/b Nsclc / Inoperable Lung Cancer, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 5
- Study locations
Study Summary
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer. There are no published human studies combining Nab-Paclitaxel (Abraxane) with radiation. The investigators will first confirm the tolerated dose (TD) of concurrent Nab-Paclitaxel (Abraxane) at 50mg/m2, and then will begin enrolling patients into the phase II component using either Nab-Paclitaxel (Abraxane) at the TD with carboplatin concurrent with daily radiation or paclitaxel with carboplatin concurrent with daily radiation.
Conditions Studied
Interventions
- DRUG PACLITAXEL
- DRUG NAB-PACLITAXEL
Study Locations (5)
Tennessee
- Sarah Cannon Research Institute - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
New York
- University of Rochester - Rochester
Pennsylvania
- UPMC Cancer Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2013-03-25 |
| Est. Completion | 2019-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01757288
The ClinicalTrials.gov registry entry for NCT01757288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage Iiia/b Nsclc / Inoperable Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which PACLITAXEL is the first listed.
NCT01757288 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01757288 about?
NCT01757288 is a clinical study titled "Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC". The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer. There are no published human studies combining Nab-Paclitaxel (Abraxane) with radiation. The investigators will first confirm th...
What is the current status of trial NCT01757288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2013-03-25. Estimated completion is 2019-06-03.
What conditions does trial NCT01757288 study?
This clinical trial studies the following conditions: Stage Iiia/b Nsclc / Inoperable Lung Cancer.
What interventions are being tested in trial NCT01757288?
The interventions under investigation include: PACLITAXEL (DRUG), NAB-PACLITAXEL (DRUG).
Who is sponsoring clinical trial NCT01757288?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01757288 being conducted?
This trial has 5 study locations across New York, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.